NeuroSense Therapeutics Ltd.
Last updated September 27, 2026
Organization details
- Legal name
- NeuroSense Therapeutics Ltd.
- Ownership
- Public
- Status
- Active
- Headquarters country
- Israel
- Ticker symbol
- NRSN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001875091
Board of directors
-
Cary J. Claiborne · DirectorSince 2026
-
Christine A. Pellizzari · DirectorSince 2026
-
Mark Leuchtenberger · DirectorSince 2026
-
Revital Mandil-Levin · DirectorSince 2026
-
Roy Golan · DirectorSince 2026
Board connections
3 of this board's directors also sit on 4 other boards.
- via Cary J. Claiborne
- via Christine A. Pellizzari
- via Roy Golan
- via Christine A. Pellizzari
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $400,000
- 2 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Ben-Noon Alon Officer (Chief Executive Officer) | Open-market purchase | +250,000 | $0.80 | $200,000 |
| Jun 16, 2026 | Eisenberg Or Officer (Chief Financial Officer) | Open-market purchase | +250,000 | $0.80 | $200,000 |
| Mar 26, 2026 | Russek-Blum Niva Officer (Chief Technology Officer) | Grant or award | +200,000 | — | — |
| Mar 26, 2026 | Binder Hagit Officer (General Manager) | Grant or award | +200,000 | — | — |
| Mar 26, 2026 | Eisenberg Or Officer (Chief Financial Officer) | Grant or award | +200,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.